Werewolf Therapeutics (HOWL) Stock: Buy, Sell, or Hold?
HOWL - Werewolf Therapeutics, Inc. Common Stock
$0.98
-0.02 (-1.71%)
▼
5d:
+0.04%
30d:
+1.77%
90d:
+166.3%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 03, 2026
15d
Get Alerted When HOWL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HOWL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HOWL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: HOWL is currently trading at $0.98, which is considered extended relative to its 30-day fair value range of $0.92 to $0.99.
Technical Outlook: Technically, HOWL is in a strong uptrend. Immediate support is located at $0.91, while resistance sits at $1.02.
Market Sentiment: HOWL scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+614.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOWL is in a strong uptrend. Immediate support is located at $0.91, while resistance sits at $1.02.
Market Sentiment: HOWL scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+614.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.92 -
$0.99
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 614.3% below Wall St target ($7.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.92 -
$0.99
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.91
Resistance Level
$1.03
Current Trend
Strong Uptrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.66
Wall Street Target
$7.00
(+614.3%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-164.8%
Share & Embed Analysis
Last updated: October 17, 2026 11:43 PM ET
Data refreshes hourly during market hours. Next update: 12:43 AM
Data refreshes hourly during market hours. Next update: 12:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOWL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 70 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 74 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 51 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 71 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$129 | 71 BUY |
